Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)

Use of Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) and Understanding Its Etiology

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01078987

Acronym

NFD

Enrollment

Registered

2010-03-02

Start date

2002-02-28

Completion date

2012-03-31

Last updated

2014-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrogenic Fibrosing Dermopathy, Nephrogenic Systemic Fibrosis

Keywords

Nephrogenic Fibrosing Dermopathy (NFD), Nephrogenic Systemic Fibrosis (NSF)

Brief summary

The purpose of this study is to evaluate the pathophysiology of nephrogenic fibrosing dermopathy (NFD)/nephrogenic systemic fibrosis (NSF).

Interventions

PROCEDUREPlasmapheresis

A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

* diagnosed with NFD/NSF following a kidney transplant * diagnosed with NFD/NSF following a liver transplant * NFD/NSF and who have not had a kidney or liver transplant * diagnosed with NFD/NSF and who have not had a kidney or liver transplant

Design outcomes

Primary

Measure	Time frame
Improve elasticity of skin, including increased range of motion of compromised joints due to leathery skin	Assessed two weeks after each monthly course of plasmapheresis

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026